<DOCUMENT>
<TYPE>EX-10.8.H
<SEQUENCE>14
<FILENAME>b323607ex10-8h.htm
<DESCRIPTION>AMENDMENT AGREEMENT
<TEXT>

<html>
<head>
<title>Prepared and filed by St Ives Burrups</title>
</head>

<body bgcolor="#ffffff">
<p align="right"><b><font size="2" face="serif">Exhibit 10.8h</font></b></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>

<p align="center"><img src="b323607x12x1.jpg" width="282" height="87"></p>
<p align="right"> <font size=2 face="sans-serif">May 15, 2000</font> </p>
<p> <font size=2 face="sans-serif">NPS Pharmaceuticals, Inc.<br>
  420 Chipeta Way<br>
  Salt Lake City, Utah 84108</font> </p>
<p> <font size=2 face="sans-serif">RE: Amendment Agreement</font> </p>
<p> <font size=2 face="sans-serif">Dear Sirs:</font> </p>
<p> <font size="2" face="sans-serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Amendment
  Agreement (hereinafter &#8220;Amendment Agreement&#8221;) will confirm that
  the November 1, 1993 Collaborative Research and License Agreement between NPS
  Pharmaceuticals, Inc., a corporation of the state of Delaware, having a place
  of business at 420 Chipeta Way, Salt Lake City, Utah 84108, U.S.A. (herein referred
  to as &#8220;NPS&#8221;) and SmithKline Beecham Corporation, a corporation of the Commonwealth
  of Pennsylvania, having a place of business at One Franklin Plaza, Philadelphia,
  Pennsylvania 19101, U.S.A. (hereinafter referred to as &#8220;SB&#8221;) as amended (hereinafter
  collectively referred to as &#8220;Original Agreement&#8221;) shall be further amended as
  follows:</font></p>
<table width="100%" align="center" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td width="3%"><font size=2 face="sans-serif">&#8226;</font></td>
    <td><font size="2" face="sans-serif">Paragraph 1.20 shall be replaced in its
      entirety with the following:</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><font size="2" face="sans-serif">&#8220;1.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;IND&#8221;
      shall mean an Investigational New Drug Application for COMPOUND in the FIELD
      filed by or on behalf of SB with the FDA or equivalent application(s) filed
      with the appropriate regulatory authorities in the United Kingdom, France,
      Germany, Italy, Spain or Japan, provided that the purpose of such IND is
      not to conduct experimental medicine based on a toxicology package insufficient
      to support multiple dose studies.</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size=2 face="sans-serif">&#8226;</font></td>
    <td><font size=2 face="sans-serif">Paragraph 5.01 shall be amended as indicated,
      additions are indicated in <b>bold text</b>, deletions are indicated by
      stike through and <b>bold text</b>:</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
</table>
<table width="100%" align="center" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td width="3%">&nbsp;</td>
    <td><font size=2 face="sans-serif">EFFECTIVE DATE</font></td>
    <td align="right"><font size=2 face="sans-serif">U.S. $ 4,000,000</font></td>
    <td width="1%" align="right">&nbsp;</td>
    <td width="12%">&nbsp;</td>
    <td width="3%">&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td align="right">&nbsp; </td>
    <td align="right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><font size=2 face="sans-serif">January 1, 1995</font></td>
    <td align="right"><font size=2 face="sans-serif"> U.S. $ 2,000,000</font></td>
    <td align="right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td align="right">&nbsp; </td>
    <td align="right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><font size=2 face="sans-serif">First Program Status</font></td>
    <td align="right"><font size=2 face="sans-serif">U.S. $ 3,000,000</font></td>
    <td align="right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td align="right">&nbsp; </td>
    <td align="right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><b><font size=2 face="sans-serif">First Experimental Medicine IND</font></b></td>
    <td align="right"><b><font size=2 face="sans-serif">U.S. $ 1,000,000</font></b></td>
    <td align="right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td align="right">&nbsp; </td>
    <td align="right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><b><font size=2 face="sans-serif">First IND</font></b></td>
    <td align="right"><b><font size=2 face="sans-serif">U.S. $ 2,000,000</font></b></td>
    <td align="right">&nbsp;</td>
    <td><b><font size=2 face="sans-serif"><strike>(3,000,000)</strike></font></b></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td align="right">&nbsp; </td>
    <td align="right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><font size=2 face="sans-serif">NDA Filing for First COMPOUND</font></td>
    <td align="right"><font size=2 face="sans-serif">U.S. $ 5,000,000</font></td>
    <td align="right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td align="right">&nbsp; </td>
    <td align="right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><font size=2 face="sans-serif">Second Program Status</font></td>
    <td align="right"><font size=2 face="sans-serif">U.S. $ 2,000,000</font></td>
    <td align="right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td align="right">&nbsp; </td>
    <td align="right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><font size=2 face="sans-serif">First IND for Second COMPOUND</font></td>
    <td align="right"><font size=2 face="sans-serif">U.S. $ 2,000,000</font></td>
    <td align="right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td align="right">&nbsp; </td>
    <td align="right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><font size=2 face="sans-serif">Third Program Status</font></td>
    <td align="right"><font size=2 face="sans-serif">U.S. $ 1,000,000</font></td>
    <td align="right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td align="right">&nbsp; </td>
    <td align="right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><font size=2 face="sans-serif">First IND for Third COMPOUND</font></td>
    <td align="right"><font size=2 face="sans-serif">U.S. $ 1,000,000</font></td>
    <td align="right">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
</table>
<p align="center"><font size=2 face="sans-serif">Page 1</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<table width="100%" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td valign="top" width="3%"><font size=2 face="sans-serif">&#8226;</font></td>
    <td valign="top"><font size=2 face="sans-serif">Add the following as new Paragraph
      5.01(1):</font></td>
  </tr>
  <tr>
    <td valign="top" colspan="2">&nbsp;</td>
  </tr>
  <tr>
    <td valign="top" colspan="2"><font size=2 face="sans-serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;(I)
      by the term "First Experimental Medicine IND&#8221; as used in this
      Paragraph 5.01 is meant the first Investigational New Drug Application for
      any COMPOUND in the FIELD filed by or on behalf of SB with the FDA provided
      that the purpose of such IND is to conduct experimental medicine human trials
      based on a toxicology package insufficient to support multiple dose studies.
      Multiple dose studies shall not include single doses separated by a wash-out
      period equivalent to at least 7 days or 5 half-lives of the COMPOUND.</font></td>
  </tr>
  <tr>
    <td valign="top" colspan="2">&nbsp;</td>
  </tr>
  <tr>
    <td valign="top"><font size=2 face="sans-serif">&#8226;</font></td>
    <td valign="top"><font size=2 face="sans-serif">This Amendment Agreement shall
      be retroactively effective as of November 1, 1993.</font></td>
  </tr>
  <tr>
    <td valign="top">&nbsp;</td>
    <td valign="top">&nbsp;</td>
  </tr>
  <tr>
    <td valign="top"><font size=2 face="sans-serif">&#8226;</font></td>
    <td valign="top"><font size=2 face="sans-serif">All other terms and conditions
      of the Original Agreement shall remain in full force and effect.</font></td>
  </tr>
</table>
<p> <font size=2 face="sans-serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
  indicate your acceptance of this</font> <font size=2 face="sans-serif">Amendment
  Agreement by signing and dating the duplicate copies of this letter below and
  returning one such fully executed copy to SB.</font> </p>
<table width="100%" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td valign="top">&nbsp;</td>
    <td colspan="2" valign="top"><font size=2 face="sans-serif">Very truly yours,<br>
      SMITHKLINE BEECHAM CORPORATION </font></td>
  </tr>
  <tr>
    <td valign="top">&nbsp;</td>
    <td colspan="2" valign="top">&nbsp;</td>
  </tr>
  <tr>
    <td valign="top">&nbsp;</td>
    <td colspan="2" valign="top">&nbsp;</td>
  </tr>
  <tr>
    <td valign="top">&nbsp;</td>
    <td valign="top"><font size=2 face="sans-serif">By:</font></td>
    <td valign="top"><font size=2 face="sans-serif"><u>/s/ Donald F. Parman</u></font></td>
  </tr>
  <tr>
    <td valign="top">&nbsp;</td>
    <td width="5%" valign="top">&nbsp;</td>
    <td width="57%" valign="top"><font size=2 face="sans-serif"> Donald F. Parman</font></td>
  </tr>
  <tr>
    <td valign="top">&nbsp;</td>
    <td valign="top"><font size=2 face="sans-serif">Title:</font></td>
    <td valign="top"><font size=2 face="sans-serif">Secretary</font></td>
  </tr>
  <tr>
    <td valign="top">&nbsp;</td>
    <td valign="top"><font size=2 face="sans-serif">Date:</font></td>
    <td valign="top"><font size=2 face="sans-serif">May 15, 2000</font></td>
  </tr>
</table>
<p> <font size=2 face="sans-serif">AGREED TO AND ACCEPTED:<br>
  NPS PHARMACEUTICALS, INC.</font> </p>
<table width="100%" border=0 cellspacing=0 cellpadding=0>
  <tr>
    <td width="5%" valign="top"><font size=2 face="sans-serif">By:</font></td>
    <td valign="top"><font size=2 face="sans-serif"><u>/s/ James K. Jensen</u></font></td>
  </tr>
  <tr>
    <td valign="top"><font size=2 face="sans-serif">&nbsp; </font></td>
    <td valign="top"><font size=2 face="sans-serif">James K. Jensen</font></td>
  </tr>
  <tr>
    <td valign="top"><font size=2 face="sans-serif">Title:</font></td>
    <td valign="top"><font size="2" face="sans-serif">Vice President</font></td>
  </tr>
  <tr>
    <td valign="top">&nbsp;</td>
    <td valign="top">&nbsp;</td>
  </tr>
  <tr>
    <td valign="top"><font size=2 face="sans-serif">Date:</font></td>
    <td valign="top"><font size=2 face="sans-serif">May 15, 2000</font></td>
  </tr>
</table>
<p align="center"><font size=2 face="sans-serif">Page 2</font> </p>
<hr noshade align="center" width="100%" size="2">
</body>

</html>


</TEXT>
</DOCUMENT>
